Qol Holdings Co., Ltd.

Qol Holdings Co., Ltd.

TTSE:3034
2,492.00
JPY
+18.00
(+0.73%)
70.04BMarket Cap
Jan 29Next Earn
Qol Holdings Co., Ltd.
TSE:3034
(Tokyo Stock Exchange)

Recent

price

2,492.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
2,461.35
2,635.42
3,002.09
3,261.28
3,359.86
3,631.14
3,876.85
4,120.71
3,767.84
4,360.72
4,305.74
4,526.25
4,598.25
4,837.03
7,051.83
7,746.2
- -
Revenue per Share
45.94
62.1
52.74
25.1
63.31
107.78
128.33
141.19
101.7
107.22
89.53
149.49
152.95
131.1
137.95
197.35
- -
Basic EPS, GAAP
37.85
50.44
115.14
5.62
178.92
164.88
120.46
264.46
107.38
75.35
287.56
228.22
193.41
301.39
-249.32
282.68
- -
Free Cash Flow per Basic Share
6.23
13.02
25.69
18.28
17.54
21.94
26.42
24.86
28.31
28.34
28.15
28.73
29.53
32.37
32.22
40.07
- -
Dividend per Share
436.07
488.84
511.32
521.52
557.35
602.28
652.38
936.69
1,006.49
1,074.58
1,124.3
1,189.66
1,314.66
1,414.42
1,521.1
1,528.86
- -
Book Value per Share
152.35
180.39
49.73
-8.54
-35.8
66.35
-249.95
208.43
225.44
102.77
170
287.58
404.5
526.58
-351.93
-332.94
- -
Tangible Book Value per Share
25
25
26
31
34
34
34
35
38
38
38
37
37
37
37
38
38
Basic Weighted Avg Shares
60,915
66,201
76,783
100,966
114,363
124,957
131,502
145,516
144,783
165,411
161,832
166,199
170,036
180,052
263,972
290,772
- -
Sales/Revenue/Turnover
4.6
5
3.66
2.09
3.71
5.4
5.22
6.25
4.87
4.68
4.55
5.93
5.58
4.62
5.1
5.09
- -
Operating Margin (%)
1,574
1,803
2,184
2,746
3,108
3,044
3,530
3,964
4,117
4,619
4,669
4,733
4,884
5,241
8,360
9,812
- -
Depreciation Expense
1,137
1,560
1,349
777
2,155
3,709
4,353
4,986
3,908
4,067
3,365
5,489
5,656
4,880
5,164
7,408
- -
Net Income, GAAP
54.3
48.17
48.92
60.38
44.26
41.5
38.58
40.33
44.58
44.42
48.47
43.27
40.95
44.91
41.77
41.08
- -
Effective Tax Rate (%)
1.87
2.36
1.76
0.77
1.88
2.97
3.31
3.43
2.7
2.46
2.08
3.3
3.33
2.71
1.96
2.55
- -
Profit Margin (%)
480
-181
283
-1,333
222
8,480
5,395
8,297
11,703
7,151
6,790
6,836
7,884
13,867
-13,854
-16,857
- -
Working Capital
3,314
3,395
8,770
9,984
12,793
18,498
27,234
16,361
19,443
21,024
18,152
14,560
14,038
23,477
19,202
18,226
- -
LT Debt
10,792
12,750
13,174
17,371
19,150
21,020
21,631
35,934
39,015
41,002
41,834
43,879
48,854
52,837
62,136
59,838
- -
Total Equity
7.72
9.26
6.19
2.77
6.56
9.3
8.19
9.12
5.91
5.88
5.07
7.81
7.81
5.72
8.14
8.43
- -
Return on Invested Capital (%)
7.33
8.94
5.99
2.75
6.31
9.13
8.77
8.71
6.1
5.55
4.46
7.99
8.23
6.33
3.18
6.54
- -
Return on Capital (%)
11.04
13.25
10.46
5.17
11.91
18.59
20.69
17.42
10.46
10.26
8.24
12.92
12.21
9.61
9.4
12.93
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
22,036
19,255
- -
LT Borrowings
15,334
18,226
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
38
38
Market Capitalization
75,374
70,045
69,969

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
56,788
59,277
- -
Cash, Cash Equivalents & STI
18,303
21,401
- -
Accounts Receivable, Net
26,177
25,826
- -
Inventories
10,698
9,966
- -
Total Current Liabilities
76,100
76,134
- -
Payables & Accruals
- -
- -
- -
ST Debt
22,036
19,255
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.3%
7.66%
-3.7%
Free Cash Flow
-8.49%
-75.42%
-213.69%
Net Income, GAAP
9.88%
20.34%
43.45%
Sales/Revenue/Turnover
9.52%
13.53%
10.15%
Total Cash Common Dividend
7.62%
7.67%
24.71%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
263,972
2026
- -
- -
- -
- -
290,772
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
137.95
2026
- -
- -
- -
- -
197.35
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
32.22
2026
- -
- -
- -
- -
40.07
2027
- -
- -
- -
- -
- -
Business
Qol Holdings Co., Ltd. (3034.T) is a Japan-based holding company primarily engaged in the pharmacy, BPO contracting, and pharmaceutical manufacturing businesses; it operates through three main segments including the management of dispensing pharmacies under the QOL Pharmacy brand, contract sales organization (CSO) services featuring contract medical representative (CMR) dispatches, contract research organization (CRO) support for clinical trials in ethical drugs, OTC drugs, functional foods, and healthcare products with strengths in food, dermatology, and ophthalmology fields, medical professional referral dispatch for pharmacists, nurses, registered sellers, and dietitians, medical-related publishing of books and magazines for professionals and patients, and manufacturing and sales of authorized generic (AG) drugs and other pharmaceuticals through subsidiaries such as DAIICHI SANKYO ESPHA CO., LTD. and Fujinaga Pharm Co., Ltd. including products like Zonisamide OD Tablets (TRERIEF OD Tablets), Phenobal, Hydantol, Fujinaga lithium carbonate, and SARS-CoV-2 antigen test kits (Tegaruna stick SARS-CoV-2 Ag); the Pharmacy Business emphasizes one-on-one pharmacies aligned with specific medical institutions for efficient operations and high-quality medication guidance, healthcare pharmacies via alliances with Lawson, BIC CAMERA, MUJI, and train stations, home medical care, community-based integrated care with visiting services and mobile sales of OTC products, certified community medical coordination pharmacies, specialized pharmacies for cancer and advanced conditions, health support functions with nutrition advice and fairs, and digital enhancements like Qol Okusuribin LINE-based prescription ordering with same-day delivery and medication records sync, plus drone delivery experiments and the November 2024 launch of Qol Dokodemo Pharmacy online service in partnership with KDDI Corporation. Founded on October 4, 1992 and headquartered at 37th Floor Shiroyama Trust Tower, 4-3-1 Toranomon, Minato-ku, Tokyo, the company lists on the Tokyo Stock Exchange Prime Market and employs approximately 5,856 regular and 2,252 temporary staff as of March 31, 2024, with operations spanning all Japanese regions from Hokkaido to Okinawa including 953 stores (931 dispensing pharmacies) concentrated in Kanto (42%), Kansai (15%), and Koshinetsu (14%) as of September 2024. Recent developments include the October 2018 transition to a holding company structure from Qol Co., Ltd., aggressive M&A expansions such as acquiring Yokohama Yakugyo Service Co., Ltd. and Yokohama Pharmaceutical Services in 2025, Dyna Co., Ltd. (18 stores in Yamanashi), Gyotoku Pharmacy Co., Ltd., and Bottom Heart Co., Ltd. (365-day pharmacies near JR Yamanote Line), ClinCloud via subsidiary APO PLUS STATION for EDC solutions and CRO data management strengthening in October 2025, additional 21% stake in DAIICHI SANKYO ESPHA in April 2024 raising ownership to 51% for consolidation (planning full ownership via further purchases funded by borrowings totaling ¥25.0 billion), launch of three new AG products at DAIICHI SANKYO ESPHA in December 2024 alongside strong June 2024 Zonisamide sales, segment reclassification in FY3/25 to highlight Pharmaceutical Manufacturing separately, and medium-term targets of ¥300 billion net sales and ¥24 billion operating income by FY3/27 through 4%+ annual pharmacy growth via 30-40 M&A stores yearly, 10% BPO organic expansion on personnel demand, and ¥100 billion sales/¥12 billion operating income at DAIICHI SANKYO ESPHA via 3-4 annual AG launches, cost reforms, and DX productivity gains.